Report to Committee on Pediatric

Oncology Subcommittee Meeting

[HTML]            [PPT]

Pamela Haylock, RN

Member, ODAC

Introduction – Accelerated Approval Process

[HTML]            [PPT]

Ramzi Dagher, M.D., Medical Officer

Division of Oncology Drug Products, FDA

EMEA Presentation

[HTML]            [PPT]

Francesco Pignatti, M.D.

Scientific Administrator

The European Medicines Agency

Sponsor Presentations and Discussion

Sponsor Presentation

DOXIL – Treatment of AIDS-related Kaposi’s Sarcoma

[HTML]            [PPT]

Johnson & Johnson, Ltd.

Wayne Rackoff, M.D.

Clinical Leader for DOXIL

Backup Slides Presented by Johnson & Johnson

[HTML] [PPT

Sponsor Presentation

Ontak ® (denileukin diftitox) Post Approval Commitments

[HTML]            [PPT]

Ligand Pharmaceuticals, Inc.

Andres Negro-Vilar, M.D., Ph.D.

Senior Vice President, Research & Development,

Chief Scientific Officer

Sponsor Presentation

Mylotarg ® (gemtuzumab ozogomicin)

[HTML]            [PPT]

Wyeth Pharmaceuticals, Inc.

Lee Allen, M.D., Ph.D.

Vice President, Medical Research

Sponsor Presentation

Depocyt: Enrollment Completed

[HTML] [PPT]

Skyepharma, Inc.

Gordon Schooley, Ph.D.

Chief Scientific Officer

Sponsor Presentation

Celebrex: Therapy of Familial Adenomatous

Polyposis (FAP), subpart H approval

[HTML]            [PPT]

Pfizer, Inc.

Craig Eagle, M.D.

Medical Director/Team Leader – Celebrex

Worldwide Oncology, Worldwide Medical

Sponsor Presentation

Campath (aletuzumab): Status of Phase IV

Postmarketing Commitments

[HTML]            [PPT]

Genzyme Corporation

Cynthia Sirard, M.D.

Medical Director, Clinical Research

Open Public Hearing Speakers

[HTML]            [PPT]

Steve Walker

Chief AdvisorAbigail Alliance Organization

[HTML] [PPT

Questions Presented After Each Sponsor Presentation

[HTML]            [PPT]

Accelerated Approval:

Questions to the Committee

[HTML]            [PPT]